top of page


News


Alpha Tau to Participate in December Investor Conferences
JERUSALEM, December 1, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will presentation in the following investor conferences in December 2025. Event: 37th Annual Piper Sandler Healthcare Conference Format: Fireside Chat Date: December 3, 2025 Time: 1:00 – 1:25PM ET Location: New York, NY Event: Sidoti's Year End Virtual
Dec 1, 2025


Interview with Dr. Philip Blumenfeld, Director of Advanced Radiotherapy Unit, Sharett Institute of Oncology, Hadassah Medical Center.
Dr. Blumenfeld*, what drew you to participate in the Alpha DaRT clinical trial for lung cancer? Alpha DaRT is a very exciting modality with significant potential for the future of radiation oncology. As radiation oncologists, we are always striving to improve what we call the therapeutic ratio: delivering a dose high enough to destroy the tumor while also minimizing harm to healthy tissues. From my experience, Alpha DaRT is unique in its ability to deliver ultra-high, highly
Nov 25, 2025


Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update
- Alpha DaRT pancreatic cancer patient treatments underway in U.S. multi-center pilot study - - Newly received radioactive material license for New Hampshire facility positions the Company for continued advancement towards commercial readiness - - Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART trial - - Cash, cash equivalents & deposits balance of $75.9 million provides runway for continued
Nov 20, 2025


Interview with Dr. Mark D'Andrea - Understanding Pancreatic Cancer
Receiving a diagnosis of pancreatic cancer can be devastating, and all too often it arrives at a stage where surgical removal is no longer an option. This is because pancreatic cancer is frequently silent until it progresses; by the time symptoms appear, the disease has often spread beyond the pancreas. Yet, despite its grim reputation, there are promising advances in both detection and treatment - from refined chemotherapy to radiation innovations and participation in clinic
Nov 19, 2025


Alpha Tau to Participate at Jefferies Global Healthcare Conference in London
JERUSALEM, November 11, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will participate at the Jefferies Global Healthcare Conference in London on November 18-19, 2025. Event: Jefferies Global Healthcare Conference Format: 1X1 Investor meetings Date: November 18-19, 2025 Location: London Mr. Levy will be available for 1x1 i
Nov 11, 2025
bottom of page




